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[Abstract] 
Concurrent chemoradiation with weekly cisplatin and daily capecitabine followed by 
intracavitary brachytherapy in the management of advanced cervical cancers  
DR SENTHILKUMARAN.M, PROF DR.S.SHANMUGHAKUMAR, 
PROF DR.N.V.KALAIARASI, DR BASKAR,  DR MADHUMATHI. DR 
PRABHAKARAN, DR SUNDARESAN, DR SANJALKUMAR, DR VIAY KARTHIK 
 
Background 
In developing countries most of the cervical cancer presents in advanced stage of disease  
Improving the therapeutic outcome of bulky cervical cancers is a big challenge  addition of 
newer chemotherapeutic agents, to increase the cure rates of bulky cervical cancers.  
Aims and Objectives:  
 To assess the clinical response rates and acute toxicity in the treatment of advanced cervical 
cancers  with concurrent chemoradiation with weekly cisplatin and daily capecitabine 
followed by intracavitary brachytherapy. 
Material & Methods 
Single arm prospective study with 30 patients with locally advanced cervical cancer 
presented to Department of Radiotherapy, Madras Medical College, Chennai 
 
Eligible patients to be treated with concurrent radiotherapy to the whole pelvis – 50Gy along 
with weekly cisplatin40mg  and daily capecitabine300mg/sqm bd  followed by intracavitary 
irradiation and assessed for response to treatment. The clinical response rates will be assessed 
after intracavitary irradiation.   
 
RESULTS 
Among the 30 patients majority of them were in the fourth decade .43% of the patient had 
stage IIB disease,56%of patient had IIIB disease overall complete response was 90%,with IIB 
disease CR [92%] IIIB disease CR[88%].100% CR in the subgroup with performance status 
>90 and age [31-40yrs].toxicities observed in the study were leucopenia grade 3 in 4 patients 
and grade 2 in 6 patients and diarrhoea grade 2 in 4 patients and grade 3 in 4 patients. 
 CONCLUSION 
In the study  patients with younger age , good performance status  with IIIB disease had 
better response rate as they were able to complete CCRT schedule with manageable toxicities 
[Abstract] 
Keywords: cervix, concurrent chemoradiation, cisplatin, capecitabine,       
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INTRODUCTION 
Cancer cervix is the second commonest malignancy among 
women globally, is the commonest malignancy to affect the female 
population in developing countries. During the past 5 decades the 
incidence of invasive cervical carcinoma has dropped dramatically 
which is attributed to the development of effective screening 
techniques for identification of pre-invasive lesions. The scenario, 
however, is still grim in the developing world wherein a 
combination of inadequate screening facilities, social stigma and 
ignorance contribute to patients presenting with locally advanced 
disease. 
NATURAL HISTORY  
INCIDENCE 
The low risk regions are Western Asia, North America, 
Australia and Newzealand. The most common cancer in women in 
Eastern Africa, South-Central Asia and Melanesia is cervical 
cancer. Overall, the mortality: incidence ratio is 52%. The death 
due to cervical cancer is 275000 in 2008. 88% of deaths occurred in 
developing countries [1]. There is a seventeen fold variation in 
mortality between the different regions of the world [Yang et al].  
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World Age Standardized Incidence Rates of Cervical Cancer 
 
 
CERVICAL CANCER BURDEN IN INDIA 
In India, cervical cancer has been the most important cancer 
in women  over the past few decades. India accounts for one fourth 
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of the global burden  The incidence rates of cervical cancer is the 
highest in 2 out of the 12  Population Based Cancer Registries 
(PBCR). It has the second highest incidence rate after breast cancer 
in the rest of the PBCRs. Chennai has the highest age adjusted 
incidence rates whereas Thiruvanathapuram in Kerala has the 
lowest (National Cancer Registry  Programme and World Health 
Organisation). North eastern districts of Tamilnadu show a higher 
incidence compared to other districts ICMR]. 
PBCR CR AAR 
Bangalore  14.3 18.8 
Barshi  20.0 22.8 
Bhopal  12.0 17.7 
Chennai  20.3 22.3 
Delhi  12.3 17.4 
Mumbai  11.5 13.9 
Ahmedabad  6.9 7.9 
Kolkata  13.2 12.3 
Dibrugarh district 3.8 5.1 
Kamrup urban district 12.8 17.3 
Silchar town 10.6 12.1 
Imphal west district 17.2 20.5 
Mizoram state 13.7 17.4 
Aizwal district 20.6 25.4 
Sikkim state 6.9 10.9 
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The burden of cervical cancer in India is disproportionately 
high Shanta etal]. The prevalence is much higher in rural India and 
among women of low socio economic status . This is due to lack of 
awareness of risk factors of the disease and lack of  access to health 
care facilities. Compliance to, and follow  up of, treatment is much 
worse for women of low socioeconomic status,  leading to further 
morbidity and mortality from the disease . Despite  having had a 
diagnosis of cervical cancer, around 40% of patients registered  in 
the Hospital Based Cancer Registries in Bangalore, Chennai and 
Mumbai  did not receive treatment at the reporting institution. Thus 
the burden of this  debilitating disease is highest in the most 
disadvantaged sections of Indian  society.  
Cervical cancer is the third largest cause of cancer mortality 
in  India after cancers of the mouth & oropharynx, and oesophagus, 
accounting  for  nearly10% of all cancer related deaths in the 
country. Among women, it  is the leading cause of cancer mortality, 
accounting for 26% of all cancer  deaths.Cervical cancer screening 
programmes have reduced mortality and morbidity from the disease 
in the developed world . However, these success stories are not 
applicable to developing countries because cytology based 
screening demands infrastructure, equipment and manpower. As a 
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result, death and disability from this cancer are high in low middle 
income countries, including India . 
ECONOMIC BURDEN OF CERVICAL CANCER  
Cervical cancer causes loss of productive life both due to  
early death as well as prolonged disability. It is responsible for 
2.7million (age weighted) Years of Life Lost (YLL) worldwide 
among women between  the ages of 25 and 64, out of which 
2.4million occur in developing areas  The Years of Life Lost (YLL) 
due to cervical cancer is greater than that  caused by any other 
cancer in India. It accounts for 4% of total YYLs due to  all causes 
in India. In India, the Years of Life Lost (YLL) due to cervical 
cancer were 936.3 in 2000, being among the highest in the world 
[Yang et al].  
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This mortality burden poses a heavy economic burden on 
families as well as the country  because women aged 25 – 64 years, 
tend to be the sole  caretakers of the house and in some cases they 
contribute significantly to the family income. Additionally, the  
high  medical  costs  that  are incurred by families due to cervical 
cancer (especially since most cases in developing countries are 
diagnosed  at  advanced  stages  when treatment  is  costly  but 
prognosis poor),further  impoverish individuals and communities 
[Bishop et al]. 
Hence it becomes imperative to identify new prevention  
strategies to reduce the risk of cervical cancer overall, to design 
new  methodologies to detect cancer early and to explore newer 
treatment options to improve the therapeutic outcome of  cervical 
cancers. 
RISK FACTORS FOR CERVICAL CANCER 
1.  Female sexual behavior  
 Sexual intercourse - This is the major prerequisite for the 
development of cancer cervix 
 Age at first intercourse  - Women who start their sexual life 
at an early age particularly before 16 years are at higher risk 
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(2.4 fold increased risk) of developing cancer cervix 
[Agarwal et al] 
 Multiple sexual partners - Cancer cervix patients usually give 
a history of  multiple sexual partners. The risk is doubled for 
women with 6 sexual partners. 
Parity - Risk factors related to parity include first childbirth 
at an early age and multiparity. 
2. Male sexual behavior (high risk male)  
High risk male sexual habits, the presence of which is associated 
with a higher incidence of cancer cervix in their spouses are  
 Sexual promiscuity: >3 extra marital partners 
 History of sexually transmitted disease 
 History of cancer penis (increases risk of cancer cervix in 
wife by 3 – 6 times) 
 History of cancer cervix in first wife (increases risk of cancer 
cervix second wife 2 fold) 
 Poor penile hygiene, Causative role of cigarette smoking in 
male and the protective effect of male circumcision are 
controversial. 
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3) Lower socio-economic group  
Women from a lower socio-economic group have a higher 
incidence (about 3 fold )of cervical malignancy due to early 
marriage, early  onset of sexual life and lack of genital hygiene. 
4)  Viral etiology  
 HPV (Human Papilloma Virus) - Among various agents, the 
HPV virus is considered to be the most likely candidate for 
etiological responsibility. Infection with HPV serotypes16 & 
18 are highly prevalent in CIN-II, III and invasive cancer 
cervix. HPV exerts its effect by P-53 gene suppression and 
inhibition of cell mediated immunity.  
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 HIV (Human immunodeficiency virus) - Women who are HIV 
positive have a 10 fold risk of cervical cancer in comparison 
with matched controls. Prevalence of cancer cervix in HIV 
positive patients below the age of 50 years is 19%. 
 HSV (Herpes simplex virus) - There is much data suggesting 
an association between cancer cervix and HSV but no 
conclusive proof is available. 
 5). Smoking  
Smoking appears to double the risk of developing cervical 
cancer [Gram et al]. Smoking constituents have been detected in 
cervical mucus.  Levels of nicotine were increased forty-fold and 
the major metabolite of nicotine, cotinine levels were increased 
four-fold in the cervical mucus of women with CIN, compared to 
serum levels[Hellberg et al].  It was found that there was increased 
DNA damage in cervical epithelium of smokers, regardless of 
concomitant HPV infection[Simons et al].  
FIGO STAGING 
0 No evidence of primary tumor;  Ca in situ 
Cervical Ca confined to uterus 
1A Invasive Ca diagnosed only by microscope 
 10 
A1 Stromal invasion not greater than 3 mm the depth and 7mm 
horizontal spread 
A2 Stromal invasion >3 mm and not more than 5 mm with 7mm 
or less    horizontal spread. 
IB Clinically visible lesions confined to Cervix or microscopic 
extension >1A 
B1 Visible lesion 4cm or less in greater dimension 
B2 Visible lesion > 4cm  in greatest dimension 
II  Tumor invades beyond uterus but not to pelvic wall or lower 
1/3 vagina 
IIA No obvious parametrial involvement. Involvement of as much 
as the upper two thirds of the vagina 
IIA1 less than or equal to 4cm 
IIA2 >4cm). 
IIB Obvious parametrial involvement but not onto the pelvic 
sidewall. 
III Tumor extends to pelvic wall  or involves lower 1/3 vagina 
causes hydronephrosis or non functioning kidney 
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IIIA Tumor involves lower 1/3 vagina not extending to pelvic wall   
III B Tumor extending to pelvic walls or causing hydronephrosis  
or non functioning kidney 
IV Tumor invades the mucosa of the bladder and rectum and or 
extends beyond the true pelvis 
IVA Tumor invades the mucosa of bladder &rectum or extends 
beyond true pelvis 
IVB Distant metastasis                                       
PROGNOSTIC FACTORS 
Identification of factors of possible prognostic significance 
may help the clinician in tailoring treatment. Patients with a low 
risk of recurrence may be subjected to less intensive treatment 
whereas patients with a high risk of recurrence may be eligible for 
clinical trials. 
TUMOR FACTORS 
Stage of the disease has been found to be a strong prognostic 
factor. As the disease advances, the prognosis becomes worse. 
Numerous studies have  indicated tumor size as a strong prognostic 
indicator for both early and locally advanced cervical cancer. 
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Tumor size more than 4 cm has been defined as bulky cervical 
cancer by FIGO and 10 year actuarial pelvic failure rates are found 
to be higher in patients with bulky cervical cancers. Another strong 
prognostic indicator is depth of invasion. Lympho vascular space 
invasion is a classical prognostic parameter in early stage cervical 
cancer. Presence of lymph node metastases has been proven to be 
of prognostic importance in several studies. In early stages, the 
depth of tumor invasion determines the incidence of pelvic lymph 
node metastases and in advanced stages, tumor volume determines 
the incidence of lymph node metastases. 
The extent of parametrial involvement was found to orrelate 
adversely with survival. A retrospective study done by Kovalic et 
al,  reported lower 10 year disease free survival for patients with 
stage IIB disease with lateral half of parametrial involvement 
compared to medial half of parametrial involvement ( 52% Vs 68%, 
p value = 0.004). Stage IIB patients whose disease extended into 
the lateral parametrium had higher total pelvic failure rates.  
The 10 year disease free survival was lower in patients with 
stage IIIB cancers with bilateral parametrial invasion compared to 
unilateral parametrial invasion [Kovalic et al]. 
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EXTENT OF PARAMETRIAL INVOLVEMENT AND 
PROGNOSIS 
Stage Extent of parametrial disease 
Survival 
(10 yr DFS) 
II B Unilateral involvement 64% 
II B Bilateral involvement 61%% 
III B Unilateral involvement 50% 
III B Bilateral involvement 34% 
A patient care evaluation study of the American College of 
Surgeons on 11,157 patients reported no significant difference in 5 
year survival among patients with squamous cell carcinoma, 
adenocarcinoma and adenosquamous carcinoma [Hugh et al]. 
However there are conflicting reports in the literature regarding the 
importance of histologic subtype as a predictor of overall survival 
in patients with cervical cancer. In contrast to other epithelial 
malignancies where histologic grading is an established prognostic 
factor, microscopic grading of cervical cancers have no prognostic 
value [Smiley et al]] 
Overall treatment time is a critical parameter which 
determines treatment outcome. Loss of local control and survival of 
1% per day when treatment exceeded 52 days has been reported in 
studies [Girinsky et al].There is controversial data in the literature 
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regarding the relationship of HPV genotype to prognosis in cervical 
cancer. However recent evidence suggests that HPV 18 positive 
cancers are associated with poor prognosis [Trimble et al]. 
Elucidation of the mechanism involved in such association could 
lead to newer treatment approaches. 
HOST FACTORS 
An association between lower socioeconomic status and 
poorer survival has been reported in several studies. Poverty and 
lower education has been associated with increased cervical cancer 
mortality [Murphy et al].  
DEATH RATES BY RACE 
Race Female 
White 2.2 per 100,000 women 
Black  4.3 per 100,000 women 
Asian/pacific islander 2.0 per 100,000 women 
American Indian/ Alaska Native 3.5 per 100,000 women 
Hispanic  3.0 per 100,000 women 
SEER Stat Fact Sheets: cervix uteri  
In multivariate analysis, hemoglobin levels at the time of 
diagnosis were associated with worse overall and disease free 
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survival. The impact of declining hemoglobin level during 
Radiotherapy on the final outcome was not observed in multivariate 
analysis [Serkies et al]. 
Smoking is a predictor of worse overall survival in patients 
with locally advanced cervical cancer treated with chemoradiation. 
Median survival was found to be 15 months shorter for smokers . 
Smoking was linked to increased cervical cancer mortality in 3 of 5 
survival analysis. A recent report found that smokers with high risk 
HPV positive cervical cancers were four times more likely to die of 
cervical cancer [Wright et al]. 
TREATMENT PRINCIPLE WITH RADIATION  
Ionizing radiation can kill cells which are actively replicating 
by two methods: 
1) Apoptosis or programmed cell death - where cells die 
immediately without dividing. 
2) Reproductive cell death - irreversible loss of reproductive 
integrity. 
These effects are brought about by the direct and indirect 
effects of radiation on cells where the DNA is the predominant 
cellular target. Direct effect of radiation - Here the ionising 
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radiation interacts directly with the critical target molecules in the 
cells (the DNA) causing excitation and ionization leading to 
biochemical lesions which lead to reproductive death of cells. The 
different types of lesions produced by radiation within the nucleus 
include – Single or double strand breaks, Base damage and Cross 
links. 
Indirect effect of radiation - Here the radiation produces 
biological damage indirectly through the formation of free radicals 
which are generated by water hydrolysis. The most common free 
radicals generated include hydroxyl ions, hydrogen ions, hydrated 
electrons and hydrogen peroxide. The damage produced by free 
radicals is promoted by the presence of O2 expressed as the oxygen 
enhancement ratio (OER) and decreased by the presence of free 
radical scavengers like sulphydryl compounds. 
FACTORS INFLUENCING THE EFFECTS OF RADIATION 
The effects of radiation on the cells are influenced by the 
following factors  
1) Dose 
2) Dose rate 
3) Radiation quality expressed in terms of LET and RBE 
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4) Repair of sub-lethal and potentially lethal damage 
5) Phase of cell cycle - Maximum cell kill due to radiation is 
obtained when cells are irradiated in the G2 and M phases of 
the cell cycle. The radiosensitivity decreases during the G l 
and early S phase and the late S phase is the most 
radioresistant phase in the cell cycle. 
6) Radiation fractionation - Based on the principles of repair, 
reoxygenation, repopulation and redistribution. 
7) Presence of O2 or free radical scavengers. 
OVERVIEW OF TREATMENT POLICY IN CANCER 
CERVIX 
All the three standard modalities of oncology namely 
radiation, surgery and chemotherapy have stamped their role in the 
treatment of different stages of the disease. 
ROLE OF SURGERY IN CANCER CERVIX THERAPY 
The role of radical surgery is limited to pre-invasive and 
early stages of invasive growth. In some selected cases it is 
combined with RT and it is used as a salvage procedure to treat 
local failure after RT.  
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In early disease surgery is preferred over RT in:  
1) Small volume disease (<4cm) 
2) Young patients for better preservation of sexual life in 
comparison to RT  
3) Endocervical cancers and adenocarcinomas 
4) Patients with co-existing diseases like uterus, ovarian 
cysts and prolapse.  
ADVANTAGES OF SURGERY IN EARLY DISEASE 
Surgery has the following advantages over RT in early 
disease: 
 Surgery is both therapeutic and a staging procedure. Based on 
findings in the post-op specimen appropriate post-op RT can 
be combined to enhance cure rates. 
 Surgery preserves the ovaries if necessary and leaves behind 
a pliable vagina which preserves the sexual life of the patient.  
 Psychological relief to the patient that the disease has been 
cured is higher with surgery. 
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ROLE OF RT IN THE THERAPY OF CANCER CERVIX 
Right from the time of its discovery nearly a century ago, 
radiotherapy has been the predominant modality used in the therapy 
of cancer cervix. Radiation finds a place in the management of all 
stages of the disease. In early disease it is an effective curative 
alternative to surgery. In locally advanced disease it is the primary 
curative modality. In metastatic disease radiation palliates local and 
distant complications. Radiation is delivered as brachytherapy 
alone, as ICA (intra cavitary application) in stage I disease or with 
ideally sequenced combinations of external beam radiation (EBRT) 
and brachytherapy in other stages. As the size of the lesion and the 
proportion of the cervix involved increases, the risk of lymph node 
involvement also increases and one has to irradiate the whole 
pelvis, covering the primary tumor, its local extension within the 
pelvis and the pelvic lymph nodes in contiguity.  
A homogenous dose distribution over such a large volume can 
be achieved only by teletherapy. The external beam radiation is 
followed by ICA to achieve the highest local control rate possible 
and this sequence is also ideal in that the tumor shrinkage caused 
by the initial EBRT will bring the anatomy to near normal resulting 
in an optimal and uniform dose distribution from a subsequent ICA. 
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EBRT is delivered before brachytherapy in patients with bulky 
primary tumors, exophytic bleeding tumors, necrotic or infected 
tumors and tumors with parametrial involvement. 
PRINCIPLE OF EBRT 
EBRT aims at producing a homogenous dose to the target volume 
which includes the primary tumor (uterus with cervix), paracervical and 
parametrial tissue, vagina if involved and regional lymph nodes. 
PRINCIPLE OF ICA 
ICA delivers a very high dose to the central tumor volume 
including the cervix and adjacent tissues with maximum tumor 
control without crossing the tolerance of surrounding normal tissue. 
This is possible because the normal uterus and vaginal vault are 
relatively radio-resistant and tolerate relatively high doses of 
radiation and there is a rapid fall of dose at a distance from the 
cervix protecting the rectum, bladder and small bowel. 
The normal tolerance doses of various organs included in the 
treatment field are as follows  
Uterus with cervix : 200 - 300Gy 
Vagina   : 160 - 200Gy 
Bladder   : 80Gy 
Rectum   : 70Gy 
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The tolerance of the rectum and bladder are the critical dose 
limiting points in the radiation of cancer cervix. 
DOSE REFERENCE POINTS 
In intra-cavitary applications the dose is prescribed to 
specific points in the pelvis namely. 
1) Point A:  connect a line through the center  of each ovoid 
or the lateralmost dwell position in the ring; extend this line 
superiorly along the radius of the ovoids (or ring), and then move 
an additional 2cm superior along the tandem. From this point, 
extend out 2 cm on each side laterally on a line  perpendicular to 
the tandem  
2) Point B – Defined as a point lying 3cm lateral to point A i.e 
5cm lateral to centre of the cervical canal and 2 cm above the 
external os. This point represents the dose received by the obturator 
node and hence is the dose prescription point for the parametrium.  
3) Bladder point – The bladder point is located using a Foley’s 
catheter with the balloon filled with 7cc contrast material and 
distilled water. In the frontal simulation film the bladder point is 
marked at the centre of the balloon. In the lateral film the bladder 
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point is marked on the posterior end of a line drawn antero-
posteriorly through the centre of the balloon. 
4) Rectal points – Three rectal points are identified on the 
frontal simulator radiograph R1 is the centre of a line joining the 
midpoint of the vaginal ovoids.R2 and R3 1cm above and below. On 
the lateral film the rectal points are identified on the horizontal line 
drawn from the middle of the ovoids to 5mm behind the posterior 
vaginal wall, 1cm above and below. The posterior vaginal wall may 
be identified by radio opaque gauze used for vaginal packing and 
rectum by rectal marker. The maximum dose received is calculated 
as rectal dose. 
5) Pelvic wall points – In the frontal simulator radiograph the 
pelvic wall point is identified at the point of intersection of a 
horizontal tangent drawn to the superior aspect of the acetabulum. 
On the lateral film this point is marked as the highest mid-distance 
point of the right and left acetabulum. 
A rectal probe is inserted to measure the dose received at the 
anterior rectal wall. This should be less than 60% of the dose 
received at point A. Computer generated isodose curves provide the 
best method of determining the doses to these various points.  
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RT REACTIONS 
Early Reactions: Include radiation proctitis, cystitis and 
ileitis. Usually they are mild and transient. Skin reactions vary from 
erythema, dry desquamation to moist desquamation and ulceration.. 
Skin morbidity can be totally avoided by proper radiotherapeutic 
techniques.  
Late Reactions: 5-10% of patients develop long term 
complication. Rectum or sigmoid colon may develop ulcerations or 
strictures. Fistulas are rare. Small bowel injury may result in 
persistent or intermittent attacks of diarrhea. Occasionally localized 
structures or perforations can occur, requiring pelvic surgery. Small 
bowel late reactions are more in patients with history of previous 
bowel surgery due to fixed bowel syndrome. The bladder morbidity 
usually manifests as repeated and self limiting attacks of 
haematuria. Vesico-vaginal fistula is usually secondary to bladder 
involvement by tumor. Hydronephrosis appearing for the first time 
after treatment is usually due to recurrent disease. 
ROLE OF CHEMOTHERAPY 
Initially chemotherapy was considered only in stage IV B  
disease to provide palliation of systemic disease. Combination of 
chemotherapy concurrently with radiation in locally advanced 
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cancer cervix is the present day rule. Recurrent cervical cancer 
after hysterectomy generally treated with radiotherapy alone has 
also been the subject of chemoradiation trials. 
As the stage and tumor bulk increases the survival rates 
worsen. Despite significant technological advances, radiation alone 
has not produced significant local control rates in locally advanced 
cancer cervix. The rates of post RT residual and recurrent disease 
continue to remain high.  
The reasons limiting the ability of RT producing desirable 
local control in locally advanced cancer cervix include increasing 
bulk of the primary lesion leading to poor tumor geometry, central 
hypoxia and low growth rate fraction. In the absence of local 
control these tumors lead to progressive pelvic disease, extra pelvic 
disease and finally death.  
Thus the survival rates are pretty poor in locally advanced 
cancer cervix in comparison with early disease. Improved local 
control is necessary to achieve significant improvement in survival.  
RATIONALE OF CONCURRENT CHEMORADIATION 
The primary rationale of chemoradiation  is  
 Established limitation of single modality treatment  
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 The desire to improve results of such therapy 
The various types of interaction could be 
 Spatial co – operation 
 Enhancement 
o Supra – additive 
o Additive 
o Sub – additive 
 Diminution 
o Inhibition 
o Anatagonism 
RADIOBIOLOGICAL MECHANISMS OF INTERACTION 
Chemotherapy when combined with radiation leads to 
enhanced cell kill by the following mechanisms: 
1. Inhibition of sub – lethal damage repair: Sublethal damage 
inflicted by radiation is reparable. The chemotherapeutic agents 
used in chemoradiation therapy interact with cellular repair 
mechanisms and inhibit repair, thereby enhancing tissue response to 
radiation. 
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2. Cell phase Re- distribution: Some drugs can block transition 
through mitosis with the result cells accumulate in G2 and M 
phases, the most radiosensitive of the cell cycle leading to 
enhanced cell kill. Elimination of radio-resistant S phase cells by 
chemotherapeutic agents is another strategy.  
3. Effects on tumor size and vascular supply:  The effect of both 
modalities is inversely proportional to tumor size. When given 
concurrently, one modality reduces the tumor size and the other 
acts with increased efficiency. 
4. Effect on repopulation: The “ accelerated repopulation” is 
the result of compensatory regenerative response caused by 
cytotoxic action of chemotherapeutic drugs or radiation. Any 
approach that reduces or eliminates clonogen repopulation in 
tumors would improve radiation response. Chemotherapeutic drugs, 
as a result of their cytotoxic or cytostatic activity can reduce rate of 
proliferation when given concurrently with radiation therapy and 
hence increasing the effectiveness of treatment.  
5. Effect on hypoxic and low pH cells: The effect of hypoxia is 
particularly pronounced in cancer cervix with regards to its 
response to radiation therapy .The presence of hypoxia makes 
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tumors more aggressive and more resistant to radiation as well as to 
most chemotherapeutic agents. Combining chemotherapeutic agents 
with radiation therapy can reduce or eliminate hypoxia or its 
negative influence on tumor radio-response. Most chemotherapeutic 
agents kill proliferating cells which are primarily found in well 
oxygenated regions of the tumor. Destruction of tumor cells in 
these areas leads to an increased oxygen supply to hypoxic regions 
and hence re-oxygenates hypoxic tumor cells making them more 
susceptible to radiation. Certain drugs that act in the acidic state of 
the tumors can also be used. 
6. Modification of apoptosis: Apoptosis is a major dynamic 
process by which radiation induces cell death. Certain drugs can 
enhance cell kill through apoptosis. 
BIOLOGICAL BASIS FOR FRACTIONATION 
From those experiments it was evident that the benefits of 
fractionation were due to four factors  
1) Repair 
2) Reassortment 
3) Repopulation 
4) Reoxygenation 
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MODELS OF FRACTIONATION 
1) The strandquist Plot 
2) The nominal standard dose system (NSD) 
3) The linear quadratic model 
Now a days the linear quadratic model is being followed. The 
L-Q model explains that the radiation cell kill has two components. 
The initial linear component, which is due to single track events, 
and the quadratic component is due to two track events.  
The linear component is denoted by  -D and the exponential 
component by –D2.  P ( Survival ) = e(-D–D2 ) where D is the total 
dose and ,  are constants which represents linear and quadratic 
components of cell kill respectively. 
The linear quadratic model explains why there are different 
responses between tumor, early responding and late responding 
tissues. Here the tumor resembles early responding tissues in 
response to radiotherapy. By dividing total dose into number of 
fractions preferentially reduces the late effects.   
Conventional fractionation means giving five fractions per 
week with dose 1.8 to 2Gy per fraction. 
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PHARMACOLOGY OF CISPLATIN  
CDDP (CIS- CHLORO- DIAMINE- PLATINUM) 
Cisplatin the platinum in each of these compound induces cell 
killing effect by the development of covalent bifunctional DNA 
adducts with cellular DNA. The cisplatinum contains two amines 
and two chloride group .cisplatin is given as single agent and also 
in combination with other drugs. 
 It is administered as IV infusion 50-75mg/m
2
 given every 3-4 
weeks or weekly 40mg/m
2
.It is given as infusion in 250ml of 
normal saline in a duration of 1-4hrs .  when infusion time is 
shorter there is more of clinical toxicity .Before infusion of 
cisplatin patient should be adequately hydrated About 2liters of IV 
fluid should be given .Mannitol 125mg is mixed with cisplatin in 
250ml of normal saline . 
Common toxicity from cisplatin is renal insufficiency with 
cation wasting nausea, vomiting, perirpheral neuropathy, auditory 
impairment, myelosuppression with low platelet count.Aggressive 
premedication for nausea is necessary before cisplatin therapy 
.5Hydroxytryptamine receptor antagonist, dexamethasone are given 
before chemotherapy to prevent vomiting. 
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5 FLUORO- URACIL     
The fluoropyrimidine shows a broad activity against a range 
of solid tumors as GI malignancy (esophageal, gastric, pancreatic, 
colorectal, anal and hepatocellular), head and neck, ovarian 
carcinoma.  
By the uracil transport mechanism 5FU enter the cells forms 
cytotoxic nucleotides by biochemical pathways and causes 
inhibition of thymidine synthase and also incorporated in RNA and 
DNA leading to genotoxic stress and cell death. 5FU is not 
administered orally as the bioavailability is erratic due to high level 
of catabolic enzymes DPD(dihydro pyrimidine dehydrogenase). 
dihydro pyrimidine dehydrogenase is higher in the gut mucosa .   
5FU is eliminated rapidly.  Half life is 8-14 minutes .  3 to 
5% of the genral population has a partial or complete  deficiency of    
DPD.  When there is deficiency of the enzyme then  they may   
have severe toxicity in the form of myelosuppression, diarrhoea, 
mucositis, and  neurotoxicity.   
CAPECITABINE  
Capecitabine a oral fluoropyrimidine carbamate . capecitabine 
is extensively  absorbed  by the  gut mucosa  .  The oral 
bioavailability is 80%.  5-deoxy 5 fluorouridine isconverted to 5FU 
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by thymidine phosphorylase.  Thymidine phosphorylase  level  is  
higher  in the  tumor  than  normal  tissue so there is increased 
availability  5FU  in the  tumor  tissue there by increasing the 
efficacy  of 5FU  and  reducing  the  toxicity  .   
Capecitabine  is mainly excreted  by kidney .  Toxicity of  
capecitabine  is  as  of 5FU  myelosuppression,    neutropenic fever  
mucositis  and alopecia.   
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LITERATURE REVIEW 
The role concurrent chemoradiation in cancer cervix has been 
under investigation by the Gynecological Oncology Group since the 
early 70s. The  early studies  were  done  with  hydroxyurea  as  a  
radiosensitise .  The combination of cisplatin with radiation in the 
treatment of cancer cervix lead to  better local control  and   
reduced distance metastasis This paved the way for further studies 
with cisplatin based chemoradiation  
GOG-85 Whitney et al study was done in FIGO stage IIB to 
IVA(negative paraaortic nodes after dissection).In the 
investigational arm along with EBRT patients were given 
cisplatin50mg/m
2
(D1&D29)+5FU4gm/m
2
 .In the control arm along 
with EBRT hydroxyurea 80mg/m
2
 was given twice weekly. The 
survival at eight year followup was 55% in the EBRT with cisplatin 
and 5FU arm verses 43% in EBRT with hydrxyurea arm. local 
control and survival were superior in the investigational arm. [1]  
In GOG-120 Rose et al study eligibility criteria was FIGO 
stage IIB to IVA . In Arm1 cisplatin40mg/m
2
 given weekly,in Arm2 
cisplatin 59mg/m
2
 ( D1&D29) + 5FU 4g/m2- over 96hrs+ 
hydroxurea 2gm/m2 twice weekly for 6weeks was given with 
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EBRT. In the control arm hydroxyurea 3gm/m2 twice weekly along 
with EBRT.   The 5year survival was 60% with cisplatin,  61% with 
cisplatin+5FU+hydroxyurea and  40% with only hydroxyurea along 
with radiation. The result shows cisplatinbased chemoradiation 
regimens improves over all survival. [2] 
In GOG123 Keys et al  women with bulky (>4cm)stage IB 
carcinoma cervix with radiographically or surgically negative 
pelvic or paraarotic nodes treated with pelvic EBRT and 
brachytherapy, followed by extrafascial hysterectomy .Trial arm 
received EBRTand brachytherapy with weekly cisplatin40mg/m2 
and control arm  treated  with RT alone.the overall survival rates 
were (78%) trial arm and (64%) control arm.[3] 
RTOG 90-01 Efiel et al conducted a  study of 389 patients 
with stage IB to IIA of >5 cm with proven positive pelvic lymph 
nodes, or stage IIB to IVA carcinoma cervix treated in the trial arm 
with RT and concomitant chemotherapy with cisplatin (75 mg/m2) 
and 4-day infusion of 5-FU (1,000 mg/m2per day) and control arm 
with only RT.Overall survival rate for women on the trial arm( 
irradiation and cisplatin/5-FU) 67% versus 41% in the irradiation 
only arm.[4] 
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Southwest Oncology Group 8797 conducted a study for 
women with FIGO stage IA2, IB, or IIA carcinoma  cervix with 
metastatic disease in the pelvic lymph nodes, positive parametrial 
involvement, or positive surgical margins at the time of primary 
radical hysterectomy with total pelvic lymphadenectomy.In the trial 
arm patients were treated with pelvic EBRT with 5-FU infusion and 
cisplatin, and control arm were treated with irradiation alone. 5-
year overall survival of 80% (pelvic EBRT with 5-FU infusion and 
cisplatin arm) versus 66%( irradiation alone arm)  favoring 
postoperative chemoradiation in high-risk patients.[5] 
A 2005 update of a meta-analysis of  CCRT and RT  found 24 
trials and concluded that chemoradiation improves overall survival 
(absolute benefits of 10%) and progression-free survival  (absolute 
benefits of 13%) whether or not cisplatin was used [6] 
A 2008 meta-analysis of the 13 trials that compared CCRT  to  
RT  found there was a 6% improvement in 5-year survival with 
CCRT. The effect was attributed to a reduction in both local and 
distant recurrence.[7] 
The current standard of care for bulky stage cervical cancer is 
concurrent chemo radiation. The 5 year survival of stage IIB 
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cancers reported by GOG85/GOG 120 studies is between 60 to 
70%, whereas RTOG 9001 reported a 5 year survival of around 
75% for stage IB and IIB cancers. The results of the above studies 
imply that there is still room for improvement. 
A study with   FIGO stage IIB, IIIA,  IIIB,  and IVA.  
Patients were   treated  with  external  beam  radiotherapy  of  
46Gy.  Intracavitary high  dose  brachytherapy  was  given  weekly.  
So  that  point  A  received  a  dose  of  30Gy .  cisplatin was given  
30mg/ m
2
 .  every week  along  with  external  beam  radiotherapy  .  
There  was  complete  response  in  88%  of  patients  at one  year  
follow  up .  At  four  year  follow  up  the  survival  was  65%    
and  24%  patients  failed  distally  .  there  was  increased  rate   of  
GI  toxicity .   The  study  concluded  that  weekly  cisplatin  with  
external  beam  radiotherapy  is  a effective  regimen  in  locally  
advanced  cancer  cervix.  [Sauhami et al] [17] 
Study  with   FIGO  stage  IB,  IIA ,  and  IIB   Patients were  
treated with  cisplatin  40mg/m
2
  weekly  and  RT.  Another  arm  
were  treated  with  only  RT .  At  5 year  follow  up  the  survival  
rate  was  59%  in  the  chemoradition  radiation  arm .  Only  RT  
arm  it was  56% .  but the  late  morbidity  was  higher  in  the  
chemoradiation  arm.  
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This was  the only  trial  that  didnot  show  survival  benefit  
with  chemoradiation . The  possible  explaination  for  no  survival 
benefit  with  chemoradiaton  was  it  was  a small  trial  compared  
to other  chemoradiation  trials  and many  patients  were  in  early  
stage  of  disease,there by reducing thesurvival advantage  of  the  
chemoradiation  arm  compared  to the only  RT  arm . [Pearcey  et 
al ][7]               
PATTERN OF FAILURE IN BULKY CERVICAL CANCERS 
Generally, optimizing primary treatment could be more 
rewarding than a deliberate post-treatment surveillance or 
aggressive salvage therapy. Locally advanced bulky cervical cancer 
is characterized by poor local control. As the tumor size increases, 
the risk for central disease recurrence is high [23].  
The recurrence risk rate peaks in the first year of follow up 
but the hazard rate comes down after 3 years of treatment. 
However, the risk of central disease recurrence beyond three years 
continues to be greater for patients with bulky tumors . Hence, 
tumor size is an important determinant of treatment outcome in 
bulky cervical cancers[ Thomas et al]. 
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Cisplatin is the cornerstone in most of the chemoradiation 
regimens used in cervical cancer.5FU was used with cisplatin  in 
the GOG trial was associated with a higher frequency of Grades 3 
and 4 toxicity compared to weekly cisplatin. Administration of 5FU 
required admission and prolonged hospital stay .now we have the 
advantage of oral 5FU in the   allowing out patient treatment  
THE RATIONAL CISPLATIN AND CAPECITABINE WITH 
RADIATION IN THIS PRESENT STUDY ARE  
Mechanism of interaction  
Cellular hypoxia, cell cycle age distribution, intrinsic radio 
sensitivity of the tumour are important factors that determine the 
sensitivity of the tumour to radiation. 
Hypoxia  
Radiation kills the cancer cells by generating reactive 
hydroxyl free radical with the cellular water. In the presence of 
oxygen, the reactive free radical will react with the DNA strand, 
resulting in permanent DNA damage. Oxygen will supply electron 
to the damaged DNA strand and destabilize the strand break. This 
enhancement effect of oxygen in radiation therapy is known as 
oxygen enhancement ratio. Without the electron supply from 
oxygen under hypoxic condition, the DNA damages induced by 
radiation could be repaired by the cancer cells.  
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Chronic hypoxia will lead to amplification of certain 
oncogenes like ras, c- myc, c-raf-1 which are responsible for 
increased resistance to radiation. Also the radiation generates 
oxygen free radicals which damages DNA. It is also postulated that 
due to hypoxia chemotherapy drug diffusion distance is increased. 
This causes decreased amount of chemotherapy drug to enter the 
actively dividing tumor cells.(21) 
Thus by combining radiation with a chemotherapeutic drug 
which is active against hypoxic cells, we can overcome this 
resistance to radiation. Cisplatin is active against hypoxic cells. 
Also Capecitabine metabolism’s the main key enzyme Thymidine 
phosphorylase expression is increased in hypoxic conditions. 
Cisplatin alkylates the DNA cause intrastrand and interstrand 
breaks, thereby makes it more vulnerable to radiation. It not only 
increases the damage caused by radiation but also inhibit repair of 
the radiation damage. Cisplatin inhibits the repair of sub lethal 
damage(SLD) and potentially lethal damage(PLD). It also causes 
inhibition of cell repopulation and modification of the slope of dose 
response curve. 
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The sensitivity to radiation varies widely depending upon 
which phase of the cell cycle, the cell lies. The G2 and M phase are 
three times more sensitive to radiation than S phase. The S phase is 
the most radioresistant phase followed by  early G1 phase. The 
exact mechanism for this is not known. This mechanism is 
exploited therapeutically in concurrent chemo radiation strategies.  
Most of the chemotherapeutic agents kill proliferating cells 
which are situated in the well oxygenated area. These areas lies 
close to capillaries hence they are easily accessible to 
chemotherapeutic agents. When these proliferative cells are killed, 
the bulk of the tumour is decreased and the interstitial pressure 
falls. This result in opening of closed capillaries and previously 
hypoxic cells become oxygenated. Since the tumour shrinks, the 
previously hypoxic areas move nearer to capillaries.  
Finally the loss of oxygenated cells results in more 
availability of oxygen to previously hypoxic cells which become 
oxygenated and susceptible to radiation. Tumour cells have 
accelerated cell proliferation, hypoxia and acidity which are not 
present in normal cells.   
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The expression of the enzyme thymidine phosphorylase is 
increased in conditions with hypoxia, poor perfusion and acidosis. 
This is the condition in most of the solid tumors .  
Due to the preferential activation the enzyme thymidine 
phosphorylase, Capecitabine concentration inside the tumor cell is 
higher compared to the normal tissues. Also the concentration of 
Capecitabine is higher than that of infusional 5FU, Capecitabine 
treatment leads to 2.9 times higher concentration of 5 FU in the 
tumor cell compared to non-malignant tissues. (45, 50) 
Study was  done to find the role of  thymidine phosphorylase, 
an angiogenic enzyme, in tumor progression. Thymidine 
phosphorylase (TP), an enzyme involved in pyrimidine metabolism 
. It is identical with an angiogenic factor, platelet-derived 
endothelial cell growth factor . The degradation product of 
thymidine generated by TP activity, has both angiogenic and 
chemotactic activity.  Inhibition of TP activity and function appears 
to be a promising approach for the chemotherapy of various 
tumors.[ Akiyama et al][14] 
Study conducted on human cervical carcinoma cell lines to 
find there expression of thymidine phosphorylase  and invasion 
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potentials. Study  revealed that  thymidine phosphorylase  gene and 
protein expression levels in cervical carcinoma cell lines were 
closely related to the number of cells that migrated and invaded. 
[Masatsugu ueda et al][11] 
 X-ray irradiation also up-regulated Thymidine 
phosphorylase  expression in several human cancer xenografts. A 
single-dose local irradiation at 5 Gy increased dThdPase levels by 
up to 13-fold at 9 days after the irradiation.the concluded 
that Combined modality treatment of cancer patients with cape-
citabine and X-ray irradiation would have greater potential 
usefulness . [Sawada N et al][9] 
A study with capecitabine, in locally advanced squamous 
cervical cancer with radiotherapy and cisplatin . In this study  
patients  were treated with cisplatin weekly at 40mg/m
2
, 
concurrently with radiotherapy and oral capecitabine daily.Two 
doses of capecitabine were studied 300 mg/m2 bid (cohort 1) and 
450 mg bid (cohort 2).patient received  whole pelvis EBRT dose of 
45Gy in 25 fractions at 1.8Gy per fraction, followed intracavitry 
brachytherapy  with doses between 24 to 30Gy to point A. 
diarrhoea  and myelosuppression  were the main toxicities in the 
study . Progression-free survival at 12 months was 69.2%, and 
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49.2% at 24 months.the over all survival was 57% at 24 months.the 
recommended dose of capecitabine in this study was 
300mg/m
2.
.[13] 
A phase II study Capecitabine-Based Chemoradiotherapy 
with Adjuvant Capecitabine for Locally Advanced Squamous 
Carcinoma of the Uterine Cervix. In this phase II study, patients 
with FIGO  stage IIB–IIIB cervical cancer received capecitabine, 
825 mg/m2 twice daily (Monday–Friday), during radiation (45 Gy 
per 25 fractions external-beam radiotherapy and 26 Gy high-dose 
rate brachytherapy to point A, maximum 8 weeks), followed by six 
cycles of capecitabine, 1,000 mg/m2 twice daily (days 1–14 every 
21 days). In this study the over all response rate was 88%and 
complete response was 80%.one year progression free survival rate 
86% and over all survival rate were 86%.oniy 5% experienced 
capecitabine related grade 3 toxicities  and only one patient had had 
hand foot syndrome.In this study the progression free survival  rate 
at 23 months was 76% compared to GOG 120 study PFS rate was 
67%[15]. 
The Capecitabine was also used in recurrent  squamous cell 
carcinoma of cervix  platinum based treatment. In a phase two trial 
of 22 patients Seventeen patients had prior radiotherapy, and 13 
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received a radiation sensitizer, whereas 2 patients underwent 
surgery exclusively and 3 patients had no prior treatment . Patient 
were treated with 50 mg/m2 of intravenous cisplatin on day 1 with 
2500 mg/m2 oral capecitabine daily in 2 divided doses for 14 
consecutive days in 21-day cycles. A median of 5 cycles was 
administered. the overall response rate was 31% with one CR and 
six PR. The study concluded cisplatin  - capecitabine  combination 
is a moderately tolerated and active regimen in advanced, 
persistent, or recurrent cervical cancer patients.[16] 
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AIM OF THE STUDY 
To assess the immediate locoregional response rates of  
advanced cervical cancers treated with chemoradiation with weekly 
cisplatin and daily capecitabine followed by intracavitary 
brachytherapy. 
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MATERIALS AND METHODS 
STUDY PERIOD 
From March 2015 upto September 2015 
ELIGIBILITY CRITERIA 
Twenty four patients with locally advanced cancer cervix who 
satisfied the following eligibility criteria were included in this study. 
1) Age: 30 - 60 years. 
2) Performance status: Karnofsky performance score ~ 80 
3) Disease stage: II B – III B 
4) Histology: squamous cell carcinoma only 
5) Haemoglobin  > 10 gm% 
6) Haematological parameters 
a. TC : 4000 and above / cubic mm 
b. PLT: 1 lakh and above / cubic mm 
c. RBC : 3 million and above / cubic mm 
7) HIV negative 
8) No history of treatment for the same complaints. 
9) Informed consent of patients is a must. 
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EXCLUSION CRITERIA  
1) Age : < 30 and > 60 years. 
2) KPS : < 80 
3) Hb : < 10 gm% 
4) Histology other than squamous cell cancer 
5) Disease stage: I, IIA & IV 
6) Patients with history of other cancers 
7) Patients with treatment history of same cancer. 
8) HIV positve patients 
9) Patients with past history of cardiac and hepatic 
disorders. 
PRE TREATMENT WORK –UP 
1) Complete clinical examination with emphasis on 
gynaecological     examination. 
2) Compete blood counts including Haemoglobin assay.  
3) Biochemical investigations to assess renal function. 
4) Cervix biopsy.  
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5) Cystoscopy. 
6) Chest X -ray 
7) CT/MRI abdomen and pelvis - to assess primary disease, 
local extension and visceral metastasis. 
8) ECG. 
9) HIV 
INTRA TREATMENT ASSESSMENT  
 Haemogram once a week to make sure that all patients had a 
TC of at least 4,000, a platelet count of 1,00,000 and a Hb 
status of 10 gm % before every chemotherapy schedule.  
 Renal function tests once a week to rule out any altered renal 
functioning during treatment. 
THERAPEUTIC PROTOCOL 
STUDY DESIGN 
All patients will be treated with external beam irradiation –  2 
Gy *25# to whole pelvis to a total dose of 50  Gy along with 
weekly cisplatin 40mg   and daily capecitabine 300 mg/sq.m. 
Patients will be assessed clinically for intracavitary brachytherapy 
and then will be treated with HDR remote after loading technique .   
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A ) EBRT Equipment Co – 60 Phoenix for Teletherapy 
B) ICA  Equipment HDR Remote after loader Ir- 192 
source HDR brachytherapy -           
EBRT PROTOCOL IN STUDY  
DOSE DETAILS 
Total dose delivered : 50 Gy   
Dose /# : 2Gy ,AP and PA portals, both 
portals     treated daily   
No of fractions : 25 
Total duration : 5 weeks 
Treatment days /week : 5 
Patients were assessed for ICA at the end of 25fractions of 
external beam radiation. 
BED VALUE CALCULATIONS FOR EBRT  
 According to  the linear –quadratic model the formula for 
calculating the biologically effective dose is 
BED =Nxd [1+d/(/)] –K[T-T0] 
Where   N  -  no of fractions 
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d   - dose per fraction 
/  -dose at which the linear and quadratic cell kills are equal 
k  -constant (Dose required /day to counter act proliferation) 
T  - Over all treatment  time   
T0 – Onset time for proliferation      
In the conventional radiotherapy  
Tumor –cancerous tissue in the cervix 
BED =25  x 2 [1+2/10]-0.5[33-28]=57.5Gy  
(/ value of tumor in cervix-10  k is constant -0.5) 
Bladder- the late responding normal tissue 
BED=25 x 2 [1 +2/4] =75  (/ value of bladder-4) 
Rectum – the late responding normal tissue 
BED =25x 2 [1+2/3.87]=75.8  (/ value of rectum-3.87) 
TREATMENTPLANNING: EBRT 
The whole pelvis including the cervix, vagina and parametria 
with the pelvic and iliac group of nodes was treated. 
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RT PORTAL MARGINS FOR EBRT 
1. Superior : L4-L5 interspace (to include all the iliac 
and  hypogastric nodes) 
2. Inferior : If vagina is free - Lower margin of 
Obturator  foramen. If vagina is involved - 
the entire vagina  upto the  introitus was 
included. 
3. Lateral : 2 cm lateral to bony pelvis. 
SIMULATION AND TREATMENT DELIVERY 
The treatment field was verified with PA simulator films in 
which the distal extension of the tumor was identified by placing a 
radio-opaque marker in the vagina. All patients were positioned in 
the prone position only with full bladder during external RT to 
exclude a greater extent of the small bowel from the treatment 
field. The AP portal was treated daily by gantry rotation of 180°.  
B)  ICA PROTOCOL 
After teletherapy the patients were assessed for intra-cavitary 
application. Those found fit were subjected to high dose rate (HDR) 
Brachytherapy. 
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1) HDR BRACHYTHERAPY PROTOCOL 
Technique  : Remote afterloading with 
Iridium-192 
No of #  : TWO ( 1 week after EBRT –1 
week apart ) 
Dose delivered to Point A : 800cGy /# -2# (26Gy LDR 
equivalent) 
SUMMATED DOSE: EBRT & HDR  ICCA IN THE STUDY 
Location Dose 
PT-A 83.2 
PT-B 65Gy 
Bladder 80Gy 
Rectum 70Gy 
CHEMOTHERAPY PROTOCOL 
Drug  : Cisplatin 
Dose : 40mg / m
2
 -weekly 
Schedule : Days1,8,15,22,29 of 
teletherapy  
Total number of chemo cycles : 5 cycles 
Drug capecitabine Dose : 300mg/m2 BD after food 
daily   
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RESULTS 
After completing the full course of chemotherapy and 
radiation, the patients were analysed for tumour regression along 
with assessment for toxic reactions 6 weeks after completion of 
treatment. 
The response was based on clinical assessment,  CT /MRI 
scan. The response was graded as follows : 
1) Complete Response: No clinicallydetectable lesion. 
2) Partial Response: 50% regression of measurable  tumour. No 
tumor area shows any progression No new area oflesion made 
out. 
3) Static Response: No change in tumour size. No tumor area 
shows any progression. No new area of lesion made out  
4) Progression : Increase in tumour size with  treatment   by 
>25% or Appearance  of lesions or Tumor induced death 
Local control was defined as achievement of disease free 
period of at least 3 months after obtaining a complete 
response. 
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CASE ANALYSIS AND RESULTS 
From March 2015 to august 2015 a total of 30 patients with 
previously untreated locally advanced cancer cervix fulfilled the 
criteria for inclusion in this trial. All thirty patients were treated 
with external beam radiation with concurrent chemotherapy 
followed by ICA with HDR brachytherapy (trial arm). All 30 
patients were available for final analysis. 
PATIENT CHARACTERISTICS 
NUMBER OF CASES-30 
1. Age Distribution 
AGE(Years) Number of cases 
31-40 12(37.5%) 
41-50 10(37.5%) 
51-60 8(25%) 
In this study we enrolled patients between 30-60 years of age. 
. Patients in the study were distributed in 4
th
 and 5
th
 decades. 
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2. Parity Status 
No of pregnancies Number of patients 
>5 pregn 2 ( 8 % ) 
3-4 pregn 19 ( 80 % ) 
1-2 pregn 9 ( 12 % ) 
All the30 patients were multiparous with 55% of patients 
having 3-4 children  
 
3. Performance Status-Karnofsky Scale 
KPS scale Number of patients 
>90 14(47%) 
80-90 16(53%) 
The general status of the patients was evaluated based on 
KPS status. 47% of  patients having performance status of above 
90. 
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4.  Haemoglobin Status 
Hb Number of patients 
10-11 g/dl 8 ( 83 %) 
11.1-12 g/dl 22 (17%) 
All the patients had Hb values  10 gms% at the start of study 
and was maintained with blood transfusions 
5. Figo Staging Of Tumours 
Clinical Stage Number of Patients 
II B 13 ( 43 %) 
IIIB 17 ( 57 %) 
All   of the patients had  either  stage II B  or III B disease, 
43% had  stage-IIB disease, 57% had stage III B disease.  
6. Parametrlal Involvement 
Parametrial Involvement Stage Number of patients 
Unilateral 
IIB 9 (38%) 
IIIB - 
Bilateral 
IIB 4 (21%) 
III B 17 (41%) 
More than 60% of patients had bilateral parametrial 
involvement. 
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8. HPE Based On Differentiation        
Differentiation No.of patients 
Well differentiated 4 (13 %) 
Moderately differentiated 19 ( 63 %) 
Poorly differentiated 7 (23  %) 
Only squamous cell cancers were included in this trial. Most 
of the patients had moderately differentiated squamous cell 
carcinoma.  
ANALYSIS OF TREATMENT RESULTS  
Analysis of immediate response was done 6 weeks after the 
end of planned treatment. This was done by clinical and 
radiological examination(CT/MRI abdomen and pelvis). All the 30 
patients completed the prescribed treatments and were available for 
final evaluation of immediate response. The over all response of 
100% seen at the end of external beam radiation was maintained 
after completion of treatment. None of the patients had static or 
progressive disease and there were no treatment-related deaths. 
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RESULTS OF STUDY 
Stage No of pts 
CR PR 
No % No % 
II B 13 12 92 1 8 
III B 17 15 88 2 12 
Total 30 27 90 3 10 
THE OVERALL COMPLETE RESPONSE-  90% 
PARTIAL RESPONSE  -    10% 
Totally 27 patients in the study attained complete response 
(90% of the total patients in the arm). These included 12 out of 13 
patients with stage IIB (92 % of all stage II B patients) and 15 out 
of the 17 patients with stage III B (88 % of all stage III B patients).  
On evaluating the response based on patient and disease 
characteristics the following information was obtained 
Response Vs Age Of Patient 
Age 
No.of patients(%) 
CR PR 
31-40 12( 100 %) - 
41- 50 9 ( 90 %) 1 ( 10 % ) 
51-60 6 ( 75 %) 2(25% ) 
COMPLETE RESPONSE AND AGE OF THE PATIENT 
There was 100% (CR) in the age group(31-40) 
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Response Vs Performance Status (KPS) 
KPS 
No.of patients(%) 
CR PR 
>90 14(100%) - 
80-90 13(86%) 3(14%) 
Complete reponse and performance status of patient  
In the present study patients with KPS of  90 %  had a CR of 
100% and  patients with a KPS of 80-90 had a CR of 86 %. 
Response Vs Hb Status 
Hb 
No.of patients(%) 
CR PR 
10-11 g/dl 6 ( 75 %) 2 ( 25 %) 
11.1-12 g/dl 21 ( 95 %) 1(5%) 
(P value=0.509-not significant) 
Hemoglobin Level and Complete Response 
The complete response rate increased with higher levels of 
hemoglobin. The trial benefited patients with Hb levels of > 11 gm 
% with a CR of 95% in this group. 
 59 
Response Vs HPE 
HPE 
No.of patients(%) 
CR PR 
Well differentiated 3 ( 75 %) 1 (25 %) 
Moderately differentiated 17 ( 89 %) 2 (11 %) 
Poorly differentiated 7 ( 100 %) - 
Complete Response and Tumor Grade 
The 100% complete response was attained in poorly 
differentiated  tumors 
Response Vs Parametrial Involvement 
P.M. involvement 
No.of patients(%) 
CR PR 
Unilateral 9 patients 9 (100 %) - 
Bilateral 2I patients 18 ( 86 %) 3 ( 14 %) 
Complete Response and Parametrial Disease 
Patients with unilateral disease had 100% complete response 
while those with bilateral disease had a complete response of 86%. 
Thus patients with unilateral disease are found to have better 
response rates .  
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Response Vs Disease Stage and Parametrial Involvement  
Stage 
Parametrial 
involvement 
Complete 
response 
Partial 
response 
IIB Unilateral  9(100%) - 
Bilateral 3(75%) 1(25%) 
IIIB Unilateral - - 
Bilateral 15(88%) 2(12%) 
 
Combined Influence of Stage and Parametrial Disease on Complete 
Response 
1) Patients with stage IIB and unilateral parametrial disease had 
100% CR. 
2) Patients with stage IIB and bilateral parametrial disease had 
75% CR.  
3) Patients with stage III B and bilateral parametrial disease had 
88 % CR 
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Number of Cycles Of Cisplatin Completed 
Number of cycle of cisplatin Number of patients 
5 CYCLES 24 
4CYCLES 5 
3CYCLES 1 
 
Number of Weeks of Capecitabine 
No: of days of Capecitabine Number of Patients 
35 DAYS 25 
28-35  4 
21-28 1 
TOXICITIES/ MORBIDITIES OBSERVED 
Acute local toxicity is done by RTOG Acute morbidity 
scoring criteria. 
SKIN REACTION 
In this study 73% of the patients had Grade 1 skin reactions 
in the form of dry desquamation, decreased sweating. Another 20% 
had patchy moist desquamation whereas only 6% of the patient had 
grade 3 confluent moist desquamation. 
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MUCOSITIS 
As expected there was high incidence of mucositis in this 
study. Nearly 56% of the study population developed grade 2 
reactions in the form patchy mucositis. Also 20% had grade 3 
confluent mucositis.There was delay in the brachytherapy  schedule 
due to mucositis .This lead to prolongation overall treatment time.   
The mucositis was  managed by douching with diluted 
hydrogen peroxide  and NSAIDs. Also Inj.Dexamethasone 8mg  i.v. 
bid was given for 4-5 days. 
Acute 
Toxicity 
Grade 
0 
Grade 1 
Grade 
2 
Grade 
3 
Grade 
4 
Grade 
5 
Skin 
Reactions 
0 22 
(73.66%) 
6 
(20%) 
0 0 0 
Mucositis 0 10 (33%) 17 
(56%) 
6 
(20%) 
0 0 
 
RECTUM 
In   the study 40% of the patients of the patients developed 
grade 1 toxicity .20% of the patients grade  2 toxicity .patients were 
managed symptomatically with loperamide.    
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BLADDER  
In the study about 36% of the patient had grade 1 toxicity as 
dysuria .symptoms were managed  with adequate hydration. 
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 
RECTUM 12 (40%) 6 (20%) 0 0 
BLADDER 11(36.6%) 0 0 0 
SYSTEMIC TOXICITY 
The treatment related systemic toxicity was assessed with 
CTCAE  
V 4.03 and presented . 
NAUSEA  
83% of the study population developed loss of appetite grade 
1 nausea during their treatment course.13% of the developed grade 
2 nausea. 
VOMITING 
80% of the patients had  grade 1(1 or 2 episode) of vomiting 
during chemotherapy mainly Cisplatin. Only 6% of the patients had 
grade 2(3 or 4 episodes) of vomiting managed by Oral Rehydration 
Salt and Inj.Ondansetron iv bid for 3 -5 days. Intravenous fluids 
were given whenever necessary. 
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DIARRHOEA 
In the study diarrhoea  was a major dose limiting toxicity .7% 
of the patients had grade 1 diarrhoea. Mostly the grade 1 diarrhoea 
is self-limiting, anti-motility drugs like Tab. Loperamide was used 
when needed. About  20% of the patients developed grade 2 
diarrhoea. 13% of patient developed grade 3 diarrhoea requiring IV 
fluids and hospitalisation.  
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 
Nausea 25 (83.33%) 4 (13.33%) 1 (3.33%) 0 
Vomitting 24 (80%) 6 (20%) 0 0 
Diahorrea 7 (23.3%) 6 (20%) 4 (13.3) 0 
HAND FOOT MOUTH SYNDROME  
The dreadful toxicity of Capacitabine hand foot mouth 
syndrome did not occur in any patients in this study. 
HEMATOLOGICAL TOXICITY 
ANAEMIA 
In this study 22 patients had hemoglobin >11g % and 13% 
had reduction in their Hb levels during treatment between 9.5 -
11g%. 6%  of the patients developed reduction in Hb levels to 
below 9g% and required Packed cell transfusion.All patients were 
given blood transfusion before there was fall in haemoglobin level. 
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Inspite of transfusion totally 19% had a fall in hemobglobin level 
requiring additional transfusion. 
ANEMIA 
Anemia Number Percentage 
Grade 0 22 73% 
Grade 1 4 13% 
Grade 2 2 6% 
Grade 3 0 0 
Grade 4 0 0 
LEUCOPENIA  
In the study leucopenia was a major toxicity .4 patients 
developed grade 3 leucopenia (1000-2000)  and were managed with 
G-CSF.for these  patient the protocol was continued after 
improvement of WBC counts.  6 patients had grade 2 leucopenia 
.10 patients had grade 1 leucopenia. This can be attributed to the 
drug capectiabine. 
NEUTROPENIA  
In the study 2 patients developed grade 2 neutropenia 
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THROMBOCYTOPENIA  
11 patients in the study developed grade 1 thrombocytopenia. 
Acute 
Toxicity 
Grade 
0 
Grade 
1 
Grade 
2 
Grade 
3 
Grade 
4 
Leucopenia 10 10 6 4 0 
Neutropenia 26 2 2 0 0 
Platelets 19 11 0 0 0 
RENAL TOXICITY 
All patients had normal renal function tests. Hence none of 
the patient developed renal toxicity.  
 67 
DISCUSSION 
  More than 80% of cervical cancer cases are known to occur 
in developing countries and around 60 – 80% of cervical cancer 
cases in india present in a locally advanced stage.In india most the 
cervical cancer cases are reported form poor socioeconomical 
status. Women form the back bone of family, cervical cancer erode 
the family socially and economically as the treatment period is 
long.  
For  eight decades, exclusive radiation was  the standard of 
care in locally advanced cervical cancer.  five randomized control 
trails  including nearly 2000 patients demonstrated  survival benefit 
with concomitant chemoradiation based on cisplatin. The findings 
from the five randomized trails were corroborated by a subsequent 
meta-analysis of 19 trials including 4,580 patients which showed an 
absolute survival benefit of 12% at 5 years .  The overall survival 
of locally advanced cervical cancer patients is 70% which suggests 
that the therapeutic protocols can be improved .  
There has been continuous efforts to improve the treatment 
results.There has been analysis of tumor characteristics which lead 
to poor results   The common  pattern of failure is local recurrence, 
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especially in bulky cervical cancers. The results treatment of 
recurrence with salvage surgery and chemotherapy the are poor.So 
strategies with combining newer chemotherapeautic agents with 
existing agents along with radiation which will  yield the highest 
pelvic tumor  control with acceptable toxicity thus tailoring to the 
patient needs.  
ANALYSIS OF RADIATION PROTOCOL             
In the concurrent setting in the management of pelvic 
malignancies,  the recommended dose is 45Gy  -50Gy.  various 
studies reported in the literature have used Conventional 
Fractionation In The Management Of Cancer Cervix 
ANALYSIS OF CHEMOTHERAPY PROTOCOL 
Chemotherapy regimens used in the earlier  studies are either 
weekly cisplatin or cisplatin/5FU. Since weekly cisplatin is 
accepted as the standard  in the concurrent setting, we preferred to 
use  weekly cisplatin 40mg
 
for a total of five cycle along with 
another chemotherapeutic agent capecitabine 
CAPECITABINE 
Capecitabine oral prodrug of 5FU, antimetabolite acts as a 
potent radiosensitizer.. Its role in metastatic and recurrent cervical 
cancer has been studied. Capecitabine as a single agent 
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concurrently with radiation has been tried in cancer cervix as it has 
radiosensitizing  effect and can be administered orally.  
But the dose of Capecitabine when used concurrently is 
reduced to 300mg/m
2
 twice daily. Also Capecitabine acts as a 
targeted therapy with its rate limiting enzyme thymidine 
phosphorylase expressed at higher levels in tumors with hypoxia, 
acidosis and low pH. This is the condition in most of the solid 
tumorsThus the concentration of Capecitabine in tumor cell is 2.9 
times higher than the normal tissues, reducing normal tissue 
toxicity. This is proved in various pharmacokinetic studies and 
trials with only Capecitabine with conventional radiation. 
 Cisplatin and 5FU have been used in three weekly regimens 
in various trials  and there has been increased toxicity due to 5FU 
and also 5FU needed intravenous administration  and the efficacy 
of this regimen is it is less toxic compared to cisplatin and 
5FU.This present study was formulated with the idea of using 
potent chemotherapy drug with radiosensitization which might have 
a better toxicity profile, better loco regional control with good 
response rates. 
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This study of concurrent chemoradiation with weekly 
cisplatin and capecitabine has shown better complete response of 
90%  this is higher compared to weekly cisplatin single agent trial 
which has complete response rate of 88% conducted in our 
department. There was no static or progressive disease in this 
study. 
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DISCUSSION OF TREATMENT RESULTS 
The detailed analysis of the case results has enabled us to 
identify certain tumor / patient characteristics which alter the 
immediate therapeutic response. 
VARIABLE CR PR 
No. of patients = 30 90% 10% 
Age 31-40yrs 100% - 
41-50yrs 90% 10% 
51-60yrs 75% 25% 
Stage  IIB 92% 8% 
IIIB 88% 12% 
KPS  >90 14(100%) - 
80-90 13(86%) 3(14%) 
Parametrial  
involvement 
Unilateral 100% - 
Bilateral 86% 14% 
As reported elsewhere in the literature we found  parametrial 
involvement as an important factor which determine the response to 
treatment .In this study we found that the response rate for patient 
with bilateral parametrial involvement was comparatively less than 
unilateral parametrial involvement 
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FACTORS ASSOCIATED WITH MORE FAVOURABLE 
RESPONSE  
1) Younger  Age Younger age patients were  better  able  to   
Withstand the chemoradiation schedule  and  also had good 
performance Status and they  completed  the  treatment  
protocol  without  any break. 
2) IIB Stage :  In this  study  even  though  IIB  patient  showed  
better Response  than  IIIB.  The  IIIB  patients  benefitted  
much  as  there Complete  response  was  88%.   
3) Performance Status: In  this  study  patients  with  good  
Performance  status  KPS>90  responded well  to  the  
treatment  Protocol  as  most  of  them  were  also  in  the 
younger  age group.  
4) Poorly Differentiated: As poorly differentiated histology is 
Sensitive to chemoradiation there was 100% complete 
response in this Study.  
Tumor factor 
Complete response rate 
Well differentiated Poorly differentiated 
Grade 75% 100% 
 
 73 
FACTORS ASSOCIATED WITH POOR RESPONSE  
1) Age 50 yrs 
2) Hb: 11 gms % 
3) KPS:  80 
4) Bilateral parametrial involvement   
5) Stage III B disease 
HEMOGLOBIN STATUS DURING TREATMENT 
Tumor factor 
Complete response rate 
10-11g/dl 11.1-12g/dl 
Anaemia during treatment 75% 95% 
In  this  study  about  6  patient  developed  grade 2  
leucopenia   , 4 patient  developed  grade 3  leucopenia and  grade 2 
neutropenia in  2 patients. So  in these  patients further dose  of  
capecitabine  withheld  after  third  week.  Pelvic RT  with  two  
radiosensitizing  drug  about  56%  of  the  study  patient  
developed  grade 2  mucositis  and  20%  developed  grade 3  
mucositis  leading  to  breaks  in  treatment  and  prolongation  of  
over  all  treatment  time.  
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Also  20%  of  the  patient  developed  grade 2 rectal  toxicity  
and  grade 2  diarrhoea, 13%  of  the  patient  developed  grade 3  
diarrhoea.    So further  dose  of  capecitabine  could  not  be  given  
in  these patients.  Other patient were able  to  complete  the  
chemoradiation  schedule.  Thought  the  treatment  related  toxicity  
developed they were  manageable. 
There wasn
,
t  any  treatment  related   death  in  this  study.  
Thus we see that the following factors have benefit from 
concurrent chemotherapy  : Clinically observed results are better in 
1) Younger patients 
2) KPS>90 
3) Stage IIIB  
But these are not statistically significant due to small sample 
size.  Comparison of immediate response  rates of various studies 
with concurrent CDDP and radiation in locally advanced cancer 
cervix reveals that the immediate complete response rates of our 
study are comparable with other studies 
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COMPARISON  WITH  INTERNATIONAL  STUDIES 
Study by 
No of 
patients 
Chemo schedule 
CR 
rates 
Runowicz 
et.al 5 
32 
CDDP 20 mg/m2 from DI-5 
every 21 days 
91 % 
Fields et 
al4 
55 
CDDP 20 mg/m2 from DI-5 
every 21 days 
87% 
Calkins 
et.al13 
30 
CDDP 50 mg/m2 D1 -17 
5 FU D2,3,4,5&18,19,20,21 
- 
Previous 
study 
26 CDDP 40 mg/m2 Weekly 88% 
Present 
study 
30 
CDDP 40 mg weekly with 
capecitabine300mg/m2 daily 
90% 
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Comparison of responses of various studies in our institution over the 
past five years  
Study 
Radiation dose 
Chemo 
Schedule 
Complete 
response Whole 
pelvis 
PM 
Point 
A 
Hyper 
fractionated RT  
50.4Gy 65Gy 82Gy - 75% 
Weekly 
cisplatin –
Conventional 
RT 
50Gy 60.Gy 76Gy CDDP 
Weekly day –
1 of every 
week 
88% 
Concurrent 
chemo with 
conventionalRT 
50Gy 60Gy 76Gy CDDP 20mg 
/m2  
D1-5 &D 21-
25 
90% 
Hyper 
fractionated RT 
with Cisplatin 
and 5 FU 
57.6Gy 65Gy 83Gy CDDP 
D1&17 5 FU 
D2,3,4,5& 
D18,19,20,21 
84% 
Present study 50Gy 60Gy 76Gy CDDP40mg 
Weekly with 
capecitabine 
300mg/m2 
daily 
90% 
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CONCLUSION 
In developing countries cervical cancer continues to be major 
health burden . in india majority of cervical cancer are diagnosed in 
locally advanced stage despite significant advancement in the 
treatment with radiation and chemotherapy ther is still room for 
improvement of results for bulky disease,  in disease free survival 
and progression free  survival ,with new chemotherapy agents along 
with standard chemoradiation with manageable toxicities 
.Additional chemotherapy agents  was added in the study to achieve 
the highest possible response rate with manageable toxicity. 
However the results need to be tested in longer number of patients 
to arrive at conclusion. 
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ANNEXURES 
A. LOCAL  
a. Skin - RTOG acute morbidity grading criteria 
Grade  Change 
0  No change over base line 
I 
Follicules, faint or dull erythema, dry desquamation, epilation, 
decreased sweating. 
II 
 Tender or bright erythema, patchy moist desquamation, moderate 
edema. 
III  Confluent, moist desquamation other than skin folds, pitting edema. 
IV  Ulceration, hemorrhage, necrosis. 
 
Mucosa - RTOG acute morbidity grading criteria 
 
Grade Change 
0 No change 
I Erythema 
II Patchy mucositis. 
III Confluent mucositis. 
IV Ulceration. 
 a. Bladder - RTOG Acute morbidity grading criteria 
Grade Change 
0 No change 
I Frequency of micturition  nocturia twice that of pre-treatment 
 frequency. Dysuria needing medication. 
II 
Frequency of micturition nocturia less frequent than every 
hour. 
 Dysuria, urgency, bladder spasm requiring local anaesthetic. 
III Frequency with urgency and nocturia hourly or more frequent. 
 
Dysuria, urgency, bladder spasm requiring regular narcotic. 
Gross 
 haematuria with I without clot passage. 
IV 
Haematuria requiring transfusion. Acute bladder obstruction 
not 
 secondary to clot passage. Ulceration or necrosis. 
 
. Rectum - RTOG acute morbidity grading criteria 
Grade Change 
0  No change 
I 
 Increased frequency or change in bowel habits, rectal 
discomfort    
 not  requiring medication. 
II 
 Diarrhoea requiring para-sympatholytic drug. Mucous 
discharge,  
 rectal I abdominal pain requiring medication. 
III 
 Diarrhohea requiring parenteral support, mucous or bloody    
 discharge requiring sanitary pads 
IV 
 Acute / sub- acute obstruction, fistula or perforation, GIT 
bleeding requiring transfusion. Abdominal pain, tenesmus 
requiring tube  decomoression or bowel diversion. 
 
e. Small bowel- RTOG acute morbidity grading criteria 
Grade Change      
0 No change      
I 
Anorexia with 5% weight loss from base line. Nausea, 
abdominal 
pain not requiring medication 
II 
Anorexia with 15% weight loss from base line. Nausea and 
vomiting 
requiring medication. 
III 
Anorexia with> 15% weight loss from base line requiring NG 
tube or parenteral support. Severe abdominal pain despite 
medication. Haematemesis, melena or abdominal distension. 
IV 
Ileus, sub-acute obstruction, perforation. GIT bleeding requiring 
transfusion. Abdominal pain requiring tube decompression or 
bowel diversion. 
HEMATOLOGIC TOXICITY 
Grade  
 
0 1 2 3 4 
HEMATOLOGIC 
WBC (X 1000)  
 
>=4.0  
 
3.0 - 
<4.0 
 
2.0 - 
<3.0  
 
1.0 - 
<2.0  
 
<1.0  
PLATELETS (X 
1000)  
 
>=100  
 
75 - 
<100  
 
50 - 
<75  
 
25 - 
<50  
 
<25 or 
spontaneous 
bleeding  
NEUTROPHILS  
 
>=1.9  
 
1.5 - 
<1.9  
 
1.0 - 
<1.5  
 
0.5 - 
<1.0  
 
<0.5 or 
sepsis  
 
HEMOGLOBIN 
(GM %)  
>11 
 
11-9.5  
 
<9.5 - 
7.5  
 
<7.5 - 
5.0  
 
- 
 
  
COMMON TERMINOLOGY CRITERIA FOR ADVERSE 
EVENTS CTCAE VERSION 4 
 
GRADE 1 2 3 4 
Nausea  
 
Loss of 
appetite 
without 
alteration in 
eating habits  
 
Oral intake 
decreased 
without 
significant 
weight loss, 
dehydration 
or 
malnutritio
n  
 
Inadequate oral 
caloric or fluid 
intake, tube 
feeding, TPN, 
or 
hospitalization 
indicated  
 
- 
Vomitin
g  
 
  1-2 
episodes  
(separate
d by 5 
minutes) 
in 24 hrs  
 
3-5 
episodes 
(separate
d by 5 
minutes) 
in 24 hrs  
 
>/=6 episodes 
(separated by 5 
minutes) in 24 
hrs,tube 
feeding,TPN or 
hospitalization 
indicated  
Life-
threatening 
consequences
, urgent 
intervention 
indicated  
 
Diarrhea Increase of 
<4 stools per 
day 
over 
baseline; 
mild increase 
in 
ostomy 
output 
compared to 
baseline 
Increase of 
4 -6 stools 
per da 
over 
baseline; 
moderate 
increase in 
ostomy 
output 
compared 
to baseline 
Increase of =7 
stools per day 
over baseline; 
incontinence; 
hospitalization 
indicated;sever
e 
increase in 
ostomy output 
compared to 
baseline; 
limiting 
self care ADL 
Life-
threatening 
consequences
; 
urgent 
intervention 
indicated 
 
 
INFORMATION TO PARTICIPANTS 
 
Title: -  “Concurrent chemoradiation with weekly cisplatin and daily 
capecitabine followed by intracavitary brachytherapy in the management of 
advanced cervical cancers.” 
 
Principal Investigator :  Dr. Senthil Kumaran .M 
 
Co-Investigator(if any) :   
 
Name of Participant  : 
 
Site :   
You are invited to take part in this research/ study/procedures/tests. The 
information in this document is meant to help you decide whether or not to take part. 
Please feel free to ask if you have any queries or concerns. 
 
What is the purpose of research? 
  Cisplatin is the cornerstone to most chemotherapeutic regimens used in 
cervical cancer therapy5 fluorouracil (5FU) may have compensated for the lower 
cisplatin dose intensity. Five-day infusions of 5FU are part of other chemoradiation 
regimens used to treat anal and oesophageal cancer, leading to improvement in local 
control and survival. However, the administration of these combination regimens 
requires either a 5-day hospital stay or insertion of a long line. The demand for 
hospital beds and the complications associated with intravenous lines make neither 
of these options ideal.  Capecitabine is an orally available, tumour-selective 
fluoropyrimidine carbamate. It is bio-activated to 5 FU by three enzymatic 
reactions. The final reaction occurs selectively within the tumours by thymidine 
phosphorylase, thus minimizing the exposure of normal tissue to systemic 5 FU. 
 
 We have obtained permission from the Institutional Ethics Committee.  
 
Study Design 
 Single arm prospective study   
 
Study Procedures 
 The study involves evaluation of concurrent chemoradition with weekly 
cisplatin and daily capecitabine in locally advanced cancer cervix with CT/MRI  
Abdomen  & Pelvis. The planned scheduled involve visits at _____,_____,____,  
and______(days/ weeks) after your initial visit. You will be required to visit the 
hospital _______ number of times during the study.  
 
 At each visit, the study physician will examine you. Some [blood / urine 
/imaging/clinical examination other] tests will be carried out at each visit. [… … ml 
of blood will be collected at each visit. Blood collection involves prick with a needle 
and syringe.] These tests are essential to monitor your condition, and to assess the 
safety and efficacy of the treatment given to you. 
 
 In addition, if you notice any physical or mental change(s), you must contact 
the persons listed at the end of the document.  
  You may have to come to the hospital (study site) for examination and 
investigations apart from your scheduled visits, if required.  
 
 
Possible risks to you – If any, Briefly mention  
 
 
Possible benefits to you - If any, Briefly mention  
  
 
Possible benefits to other people  
 The results of the research may provide benefits to the society in terms of 
advancement of medical knowledge and/or therapeutic benefit to future patients.  
 
Confidentiality of the information obtained from you 
 You have the right to confidentiality regarding the privacy of your medical 
information (personal details, results of physical examinations, investigations, and 
your medical history). By signing this document, you will be allowing the research 
team investigators, other study personnel, sponsors, Institutional Ethics Committee 
and any person or agency required by law like the Drug Controller General of India 
to view your data, if required. 
 
 The information from this study, if published in scientific journals or 
presented at scientific meetings,  will not reveal your identity. 
 
How will your decision to not participate in the study affect you? 
 Your decision not to participate in this research study will not affect your 
medical care or your relationship with the investigator or the institution. You will be 
taken care of and you will not loose any benefits to which you are entitled.  
 
Can you decide to stop participating in the study once you start? 
 The participation in this research is purely voluntary and you have the right 
to withdraw from this study at any time during the course of the study without 
giving any reasons. However, it is advisable that you talk to the research team prior 
to stopping the treatment/discontinuing of procedures etc. 
 
 
 
 
Signature of Investigator                                              Signature of Participant   
 
Date                                                                              Date   
 
INFORMATION SHEET 
 
• You have been accepted by the Department of Radiotherapy to enrol into the 
study “Concurrent chemoradiation with weekly cisplatin and daily 
capecitabine followed by intracavitary brachytherapy in the 
management of advanced cervical cancers.” 
 
• We are conducting a study on cervical cancers among patients attending 
Government General Hospital, Chennai.  
 
• The purpose of this study is to find if adding daily capecitabine in concurrent 
chemoradiation in cervical cancers will have a better response rates and 
lower recurrences.  
 
• We are selecting certain cases and if your case is found eligible, we may be 
performing extra tests and special studies which in any way do not decrease 
your chance of optimum treatment.   
 
• The privacy of the patients in the research will be maintained throughout the 
study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared.  
 
• Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled.  
 
• The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may 
aid in the management or treatment.  
  
 
 
 
 
Signature of investigator             Signature of participant  
INFORMED CONSENT FORM 
 
Title of the Study:  
 CONCURRENT CHEMORADIATION WITH WEEKLY CISPLATIN 
AND DAILY CAPECITABINE FOLLOWED BY INTRACAVITARY 
BRACHYTHERAPY IN THE MANAGEMENT OF ADVANCED 
CERVICAL CANCERS. 
 
NAME OF THE PARTICIPANT: 
 
NAME OF THE PRINCIPAL (Co – Investigator): DR. SENTHIL KUMARAN 
.M 
 
NAME OF THE INSTITUTION: MADRAS MEDICAL COLLEGE 
 
_____________________________ have read the information in this form (or it has 
been read to me). I was free to ask any questions and they have been answered. I am 
over 18 years of age and, exercising my free power of choice, hereby give my 
consent to be included as a participant in “Concurrent chemoradiation with weekly 
cisplatin and daily capecitabine followed by intracavitary brachytherapy in the 
management of advanced cervical cancers.” 
 
1.  I have read and understood this consent form and the information provided to 
me. 
2.  I have had the consent document explained to me. 
3.  I have been explained about the nature of the study. 
4.  I have been explained about my rights and responsibilities by the investigator. 
5.  I have been informed the investigator of all the treatments I am taking or have 
taken in the past________ months including any native (alternative) treatment. 
6.  I have been advised about the risks associated with my participation in this 
study.* 
7.  I agree to cooperate with the investigator and I will inform him/her 
immediately if I suffer unusual symptoms. * 
8.  I have not participated in any research study within the past 
_________month(s). * 
9.  I have not donated blood within the past _______ months—Add if the study 
involves extensive blood sampling. * 
10.  I am aware of the fact that I can opt out of the study at any time without 
having to give any reason and this will not affect my future treatment in this 
hospital. * 
11.  I am also aware that the investigator may terminate my participation in the 
study at any time, for any reason, without my consent. * 
12.  I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the sponsors, 
regulatory authorities, Govt. agencies, and IEC. I understand that they are 
publicly presented. 
13.  I have understand that my identity will be kept confidential if my data are 
publicly presented 
14.  I have had my questions answered to my satisfaction. 
15.  I have decided to be in the research study. 
 
 I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given in this 
document has been clearly explained to me and understood by me, I will be given a 
copy of this consent document 
 
 
 
Name and signature / thumb impression of the participant (or legal representative if 
participant incompetent) 
 
 
 
Name ________________ Signature_________________ Date________________ 
 
 
 
Name and Signature of impartial witness (required for illiterate patients): 
 
 
Name ________________ Signature_________________ Date________________ 
 
 
 
 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent: 
 
Name ________________ Signature_________________ Date________________ 
 
 
ஆராய்ச்சி தகவல் தாள் 
 
ஆராய்ச்சியின் பெயர்:  
 ப஧ண்க஭ின் கருப்ப஧ வானில் ஏற்஧டும் புற்றுந஥ாய்க்கு பவ஭ி 
கதிர்வசீ்சு சிகிச்பசம௃டன் Áõµ¢÷uõÖ® ]ì¤Íõmiß ©ØÖ® vÚ¬® 
÷P¨]hõ¤ß ஆகின புற்றுந஥ாய்க்கா஦ நருந்துகப஭ பகாடுத்த ஧ி஫கு 
"஧ிநபகிபதப஧ி" ௭஦ப்஧டும் ௨ள் கதிர்வசீ்சு சிகிச்பச ௮஭ித்து 
புற்றுந஥ாபன குணப்஧டுத்துவது ஧ற்஫ின ஆபாய்ச்சி. 
 
ஆராய்ச்சியாளர் பெயர்: 
 
ெங்ககற்ொளர் பெயர்: 
 பசன்ப஦ இபாஜவீ்காந்தி ௮பசு ப஧ாது ந௫த்துவநப஦க்கு வரும் 
புற்று ந஥ானா஭ிக஭ிடம் கதிர்வசீ்சு சிகிச்பசப் ஧ற்஫ின ஆபாய்ச்சி . 
 
 ப஧ண்க஭ின் கருப்ப஧ வானில் ஏற்஧டும் புற்றுந஥ாய்க்கு ஧஬ 
வபகனா஦ கதிர்வசீ்சு சிகிச்பச முப஫கள் ௨ள்஭஦.முத஬ில் பவ஭ி 
கதிர்வசீ்சு சிகிச்பசம௃டன் Áõµ¢÷uõ¸® ]ì¤Íõmiß ©ØÖ® vÚ¬® 
÷P¨]hõ¤ß ஆகின புற்றுந஥ாய்க்கா஦ நருந்துகப஭ பகாடுத்து 
புற்றுந஥ானின் ௮஭பவ குப஫த்த ஧ி஫கு "஧ிநபகிபதப஧ி" ௭஦ப்஧டும் ௨ள் 
கதிர்வசீ்சு சிகிச்பச ௮஭ித்து புற்றுந஥ாபன குணப்஧டுத்துவது ஧ற்஫ி 
ஆபாய்வது இந்த ஆபாய்ச்சினின் ந஥ாக்கம். 
 
 ஥ீங்களும் இந்த ஆபாய்ச்சினில் ஧ங்நகற்க  விரும்புகிந஫ாம்.இந்த 
ஆபாய்ச்சினில் தீவிப  கதிர்வசீ்சு சிகிச்பச ௮஭ித்து சி஬ சி஫ப்பு  
஧ரிநசாதப஦க்கு ௨ட்஧டுத்தி ௮தன் தகவல்கப஭ 
ஆபாய்நவாம்.இத஦ால் தங்கள்  ந஥ானின் ஆய்வ஫ிக்பகநனா 
சிகிச்பசநனா ஧ாதிப்பு  எற்஧டாது என்஧பத  பதரிவித்துக் பகாள்கிந஫ாம். 
 
 முடிவுகப஭ ௮ல்஬து கருத்துகப஭ பவ஭ினிடும் ந஧ாநதா 
௮ல்஬து ஆபாய்ச்சினின் ந஧ாநதா தங்க஭ின் ப஧னபபநனா ௮ல்஬து 
௮படனா஭ங்கப஭நனா பவ஭ினிட நாட்நடாம் ௭ன்஧பதம௃ம் 
பதரிவித்துக் பகாள்கிந஫ாம். 
 
           இந்த சி஫ப்பு ஧ரிநசாதப஦க஭ின் முடிவுகப஭ம௃ம் ந஥ானின் 
தன்பந ஧ற்஫ிம௃ம் ஆபாய்ச்சினின் முடிவின் ந஧ாது தங்களுக்கு 
௮஫ிவிப்ந஧ாம் ௭ன்஧பதம௃ம் பதரிவித்துக் பகாள்கிந஫ாம். 
 
 
 
                                 
ஆபாய்ச்சினா஭ர் பகபனாப்஧ம்      ஧ங்நகற்஧ா஭ர்  பகபனாப்஧ம்  
 
நததி:           
            
ஆபாய்ச்சி ஒப்புதல்  கடிதம் 
 
கருப்ப஧ வாய் புற்றுந஥ாய்க்கு பவ஭ி கதிர்வசீ்சு சிகிச்பசம௃டன் 
Áõµ¢÷uõÖ® ]ì¤Íõmiß ©ØÖ® vÚ¬® ÷P¨]hõ¤ß ஆகின 
புற்றுந஥ாய்க்கா஦ நருந்துகப஭ பகாடுத்து புற்றுந஥ானின் ௮஭பவ 
குப஫த்த ஧ி஫கு "஧ிநபகிபதப஧ி" ௭஦ப்஧டும் ௨ள் கதிர்வசீ்சு சிகிச்பச 
௮஭ித்து பசய்னப்஧டும் ஆய்வு. 
 
ப஧னர்:        நததி: 
 
வனது:        ௨ள்/பு஫ 
ந஥ானா஭ி எண்: 
 
஧ால்:        ஆபாய்ச்சி நசர்க்பக 
எண்: 
 
 இந்த ஆபாய்ச்சினின் விவபங்களும் ௮தன் ந஥ாக்கங்களும் 
முழுபநனாக ௭஦க்கு வி஭க்கப்஧ட்ட஦. 
 
 ௭஦க்கு வி஭க்கப்஧ட்ட விவபங்கப஭ ஥ான் புரிந்துபகாண்டு ௭஦து 
சம்நதத்பத பதரிவிக்கிந஫ன். 
 
 ௭஦க்கு புற்றுந஥ாய் இருக்கும் ஧குதினில் கதிர்வசீ்சு சிகிச்பச 
பசய்து பகாள்஭ சம்நதம். 
 
 இந்த ஆபாய்ச்சினில் ஧ி஫ரின் ஥ிர்ப்஧ந்தநின்஫ி ௭ன் பசாந்த 
விருப்஧த்தின் ந஧ரில் ஧ங்கு ப஧றுகிந஫ன்.இந்த ஆபாய்ச்சினில் இருந்து 
஥ான் ௭ந்ந஥பமும் ஧ின்வாங்க஬ாம் ௭ன்஧பதம௃ம் ௮த஦ால் ௭ந்த 
஧ாதிப்பும் ஏற்஧டாது ௭ன்஧பதம௃ம் ஥ான் புரிந்து பகாண்நடன். 
 
 ஥ான் கருப்ப஧ வாய் ஧குதினில் முற்஫ின புற்று ந஥ாய் கு஫ித்த 
இந்த ஆய்வுக்கா஦ விவபங்கள் பகாண்ட தகவல் தாப஭ப் ப஧ற்றுக் 
பகாண்நடன். 
 
 ௭஦க்கு இந்த ஆபாய்ச்சினில் தீவிப கதிர்வசீ்சு சிகிச்பச நற்றும் 
புற்றுந஥ாய் நருந்துகள் ப஧ற்றுக் பகாள்஭ சம்நதம். 
  இந்த ஆபாய்ச்சினி஦ால் ஏற்஧டும் ஥ன்பநகப஭ம௃ம் , சி஬ 
஧க்கவிப஭வுகப஭ம௃ம் ஧ற்஫ி பத஭ிவாக நருத்துவர்  மூ஬ம் 
பதரிந்துபகாண்நடன். 
 
 ஥ான் ௭ன்னுபடன சுன஥ிப஦வுடனும் நற்றும் முழு 
சுதந்திபத்துடனும் இந்த நருத்துவ ஆபாய்ச்சினில் ௭ன்ப஦ நசர்த்துக் 
பகாள்஭ சம்நதம் பதரிவிக்கிந஫ன்.       
        
                               
  
ஆபாய்ச்சினா஭ர் பகபனாப்஧ம்      ஧ங்நகற்஧ா஭ர்  பகபனாப்஧ம்  
 
நததி:   
 
 
 
 
 
 
 
 
 
 
 
 
 
